Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence

CONCLUSIONS: The benefit of roflumilast in moderate-to-severe exacerbations was estimated to be greater in specific subgroups of patients with COPD. Personalised approaches to roflumilast based on clinical phenotypes would be effective for COPD.PMID:38505074 | PMC:PMC10944795 | DOI:10.21037/jtd-23-1129
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Authors: Source Type: research